XAVIS Q1 2026: Revenue up 19% but operating loss continues, cash declines

Separate: Revenue 5.52bn KRW (+19% YoY), operating loss 0.52bn, net loss 0.38bn
Consolidated: Revenue 5.27bn, operating loss 0.77bn, net loss 0.62bn (loss widened YoY)
Cash & cash equivalents 1.02bn (sharp decline from 4.38bn at year-end)
Total borrowings 2.20bn (up from 1.50bn), total financial liabilities including leases 7.83bn
Inventories 13.18bn (up from 11.32bn), allowance for doubtful accounts 1.03bn
R&D expenses 1.18bn (21.4% of revenue), stock compensation 0.24bn
No dividend or share buyback/retirement plans
Ongoing supply contract for battery X-ray inspection equipment (~$15.54M)
New businesses: low-dose radiation dementia treatment medical device and explosive detection module development (targeting 2027 sales)
Over 100 patents, strong technology competitiveness